ENVALITH
株式会社シード logo

SEED CO.,LTD.

7743・Standard Market・Precision Instruments

Official website
株式会社シード logo
SEED CO.,LTD.7743

Business

SEED Co., Ltd. is a contact lens specialist manufacturer founded in 1957, engaged primarily in the research and development, manufacturing, and sales of hard, soft, disposable, and orthokeratology lenses, among others. Domestically, the company operates the Konosu Research Institute in Saitama Prefecture as its production base, offering domestically manufactured brands such as the SEED 1dayPure Series and the SEED AirGrade Series. Overseas, the company operates through a group structure of 18 companies spanning the UK, Germany, Switzerland, Taiwan, Singapore, Malaysia, Vietnam, China, and Hong Kong, advancing its global expansion with a focus on Asia. Its major customers are distribution businesses such as HOYA Corporation (14.8% of sales) and Palente Co., Ltd. (13.3% of sales), through which products ultimately reach contact lens wearers. Consolidated net sales for FY2026 (ending March 2026) were ¥33,942 million.

Business Model

Based on in-house manufacturing at the Konosu Research Institute (maximum monthly production of 65 million units, expanding to 79 million units once Building No. 4 becomes operational), the company is expanding high-value-added products such as specialty lenses (for astigmatism and presbyopia) and Orthokeratology Lenses (Breath O Correct®), sold through domestic distribution wholesalers, ophthalmology clinics, and mass retail channels. Overseas, sales are conducted through local subsidiaries and distributors, converting the benefits of yen depreciation into export competitiveness. The company continues to invest ¥2,075 million in R&D expenses and also holds a pipeline of next-generation products, including new materials and smart contact lenses.

Company Strengths

The mainstay 'SEED 1dayPure Series' has clear differentiation from competitors through being 'domestically produced' and offered in '32-lens packs,' with sales of toric and multifocal lenses on a recovery trend. In FY2026 (ending March 2026), the Contact Lenses & Care Products segment posted sales of ¥33,849 million (up 2.2% year on year) and operating income of ¥3,469 million (up 8.5% year on year), showing improved profitability.

With Konosu Laboratory Building No. 4 completed in January 2026 and operational from March, the company plans to raise maximum monthly production capacity in stages from 65 million units to 79 million units in FY2027 (ending March 2027) and 89.5 million units in FY2028 (ending March 2028). Total capital expenditure in FY2026 (ending March 2026) reached ¥12,359 million, with the construction of labor-saving production lines also proceeding in parallel.

R&D is promoted through a four-site structure comprising Konosu Laboratory (89 R&D staff), UK-based CLPL (4 staff), Germany-based Woehlk (3 staff), and Switzerland-based Sensimed (5 staff). R&D expenses in FY2026 (ending March 2026) totaled ¥2,075 million. The company continues to invest in next-generation products, including clinical trials for myopia progression control lenses, the release of a general-purpose platform for smart contact lenses, and the start of practical implementation of an AI-based automated appearance inspection system.

ENVALITH's Perspective

In FY2026 (ending March 2026), revenue increased to ¥33,942 million (up 2.1% year on year), but operating profit declined to ¥1,439 million (down 7.8% year on year), marking the second consecutive year of profit decline. This resulted from a combination of factors including higher import procurement costs due to yen depreciation, increased personnel expenses, and temporary costs such as launch expenses for the Singapore logistics hub and advisory fees related to organizational restructuring. For FY2027 (ending March 2027), the company projects a substantial recovery, with revenue of ¥37,000 million (up 9.0%) and operating profit of ¥2,200 million (up 52.8%); however, this forecast is premised on the simultaneous achievement of full utilization of Building No. 4's production capacity and sales expansion, and the probability of realizing this needs to be closely examined.

With the completion of Building No. 4 and the introduction of new equipment, property, plant and equipment surged from ¥27,827 million to ¥36,825 million, expanding total assets to ¥62,500 million. The equity ratio declined from 34.9% to 30.8%, and the interest coverage ratio also worsened from 8.8x to 6.9x. Operating cash flow contracted to ¥2,690 million (from ¥2,978 million in the previous period), with an increase in inventories (¥1,785 million) putting pressure on funds. Cash and cash equivalents decreased from ¥7,078 million to ¥4,171 million, and the situation calls for close monitoring of the decline in financial flexibility during this period of capital expenditure ahead of returns.

Against the final-year target of consolidated revenue of ¥50 billion (¥50,000 million) under the medium-term management plan (April 2024 to March 2027), actual revenue for FY2026 (ending March 2026) of ¥33,942 million shows a significant shortfall. The change from the TSE Prime Market to the TSE Standard Market effective March 31, 2026 (due to non-compliance with listing maintenance criteria for tradable share market capitalization) also heightens the risk of exclusion from institutional investors' investment universe. The market-value-based equity ratio stands at a low 29.4%, and investors are calling for the disclosure of concrete measures toward management that is conscious of the cost of capital.

Growth Strategy

A three-pronged strategy combining phased production capacity expansion, strengthening of high value-added lenses, and accelerated overseas expansion.

Building No. 4, completed in January 2026 and to begin operations in March 2026, will expand maximum monthly production capacity from 65 million units to 79 million units in FY2027 (ending March 2027). Following completion of the second-phase plan, capacity is expected to reach 89.5 million units per month in FY2028 (ending March 2028). The company is simultaneously advancing the construction of labor-saving production lines to maintain cost competitiveness amid a difficult labor recruitment environment.

The company is focusing on sales of specialty lenses such as toric (astigmatism) and multifocal (presbyopia) lenses. In February 2026, it launched the "SEED AirGrade 2week UV W-Moisture TORIC" to expand market share in both the 1-day and 2-week categories. A new silicone hydrogel lens material is currently under application for approval, with preliminary sales planned for FY2027 (ending March 2027) and nationwide launch planned for FY2028 (ending March 2028).

The company is revising the marketing strategy for its flagship brand, rebuilding brand image and product value while leveraging the product's key features of being "domestically produced" and "packaged in 32 lenses per box." It is also stepping up promotional activities utilizing web advertising and other channels to strengthen differentiation against price competition.

The company newly consolidated Scotlens Holdings Limited (UK, specialty lens manufacturing) and Shanghai Huanying Trading Co., Ltd. (China, wholesale). It plans to build a logistics hub in Singapore to strengthen sales in Southeast Asia (Vietnam and Malaysia). In China, the company aims to improve decision-making speed and drive sales growth through full subsidiary conversion and the establishment of a new China sales department.

The company continues to create demand for orthokeratology lenses by expanding the number of participating facilities, promoting subscription-based services, and giving presentations at academic conferences. It is also conducting clinical trials on contact lenses aimed at confirming their effect in suppressing myopia progression, making advance investments toward future expansion of indications.

Last updated: July 19, 2026